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Abstract
The Ewing Sarcoma Family Tumors (ESFT) consist of the classical pathologic entities of Ewing Sarcoma and peripheral
Primitive Neuroectodermal Tumor. Occurring largely in the childhood through young adult years, these tumors have an
unsurpassed propensity for metastasis and have no defined cell of origin. The biology of these aggressive malignancies
centers around EWS/FLI1 and related EWS/ETS chimeric transcription factors, which are largely limited to this tumor class.
Much progress has been made in the identification of a network of loci whose expression is modulated by EWS/FLI1 and its
congeners. To date, little progress has been made in reconstructing the sequence of direct and indirect events that produce
this network of modulated loci. The recent identification of GLI1 as an upregulated target of EWS/ETS transcription factors
suggests a target which may be a more central mediator in the ESFT signaling network. In this paper, we further define the
relationship of EWS/FLI1 expression and GLI1 upregulation in ESFT. This relationship is supported with data from primary
tumor specimens. It is consistently observed across multiple ESFT cell lines and with multiple means of EWS/FLI1 inhibition.
GLI1 inhibition affects tumor cell line phenotype whether shRNA or endogenous or pharmacologic inhibitors are employed.
As is seen in model transformation systems, GLI1 upregulation by EWS/FLI1 appears to be independent of Hedgehog
stimulation. Consistent with a more central role in ESFT pathogenesis, several known EWS/FLI1 targets appear to be
targeted through GLI1. These findings further establish a central role for GLI1 in the pathogenesis of Ewing Tumors.
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Introduction
Much of the unique biology of the Ewing Sarcoma Family Tumors
(ESFT) stems from the unique effects of EWS/FLI1. This fusion
transcription factor, along with related EWS/ETS fusions, is virtually
pathognomonic of these aggressive malignancies[1]. Given the nature
of these chimeric proteins, considerable work has gone into the
identification of the transcriptional targets of EWS/FLI1[2,3]. Despite
this effort, no identified target has been clinically demonstrated to be
of prognostic or therapeutic significance. Together, this diverse group
of targets constitute a signaling network. Elements of this transcrip-
tional network have been identified[3] but the relationship between
these elements has not been well studied. In a sense, such relationships
constitute the topology of this network. Based on the biology of this
disease, one can presume that EWS/FLI1 will be central to this
network. But targets of EWS/FLI1 will vary in importance from
isolated clients on the network to more centrally situated hubs or
routers which regulate a subdomain of this network in concert.
Establishing the existence and nature of such relationships will be
critical to prioritizing which transcriptional targets are most likely to
have maximal impact as targets for translational therapeutics.
The recent finding that EWS/FLI1 enhances expression of
GLI1 presents a potential clue to the interpretation of this
network[4,5]. GLI1 is the principal transcriptional effector of the
Hedgehog-GLI (HH-GLI) signaling pathway[6]. This pathway is
of critical importance in many developmental processes and is
important in the maintenance of stem cell compartments in both
developing and mature tissues[7]. Furthermore, HH-GLI has been
found to be involved in many human cancers from prostate cancer
in adults to childhood medulloblastoma[8]. Translational efforts to
target this pathway are ongoing[9,10,11]. While it has been
implicated in EWS/FLI1 biology, much of this data comes from a
murine model system for EWS/FLI1 transformation[4]. The
establishment of the significance of GLI1 upregulation to ESFT
biology remains to be more firmly established. Beyond this, if
GLI1 is more than a peripheral event in the EWS/FLI1 signaling
network, it can be expected to to leave an identifiable trans-
criptional footprint which may encompass some previously
identified EWS/FLI1 targets.
Here we demonstrate that ESFT primary tumors express HH-
GLI pathway members in a manner consistent with that seen in
model transformation systems. The EWS/FLI1 dependence of
GLI1 expression and signaling in multiple ESFT cell lines is clearly
demonstrated. Using multiple means of GLI1 inhibition, we
demonstrate the importance of GLI1 to the ESFT tumorigenic
phenotype. Intriguingly, we show that GLI1 upregulation in ESFT
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7608is a Hedgehog independent phenomenon in ESFT, suggesting
non-canonical mechanism of pathway activation. Finally, in
multiple ESFT cell lines, we demonstrate that several loci known
to be transcriptionally modulated by EWS/FLI1 are dependent
upon GLI1 expression. This establishes GLI1 as a higher order
target in the EWS/FLI1 signaling network and begins to define a
hierarchy in the EWS/FLI1 signaling network.
Results
Primary tumors demonstrate significant GLI1 expression
Our earlier findings focused on EWS/FLI1 activation of GLI1
in an NIH3T3 model transformation system[4] with added data
from ESFT cell lines. However, HH-GLI pathway activity has
been found to be diminished in in vitro cultured medulloblastoma
lines[12], so the cell lines we evaluated may not reflect the
condition in primary ESFT. To see how well these findings apply
to clinical disease, we evaluated the status of a panel of 12 ESFT
primary tumor specimens. As is illustrated in Figure 1, the
expression of mediators of the HH-GLI pathway closely resembles
that found in EWS/FLI1 expressing NIH3T3 cells. The most
characteristic indicators of oncogenic signaling via this pathway
are the expression levels of GLI1, GLI2 and the direct GLI1 target
Patched1. These are important components of what has been
termed the GLI code[13]. In these twelve ESFT specimens, we
found expression levels of these pathway mediators to be similar or
higher than those in specimens from cell lines known to be in the
upper quartile for expression in microarray data obtained for the
NCI-60 panel of tumor cell lines (Novartis, http://wombat.gnf.
org). Our earlier data from NIH3T3 indicated little or no
expression of Sonic Hedgehog (SHH)[4], which mediates pathway
activity in development and in some tumor systems. Once again,
our primary tumor specimens demonstrate very little to no
expression of SHH transcript when compared to a positive control
expressing SHH cDNA. Similar low levels of Indian Hedgehog
(IHH) were also found (data not shown). Some of the variability of
expression of GLI pathway members from sample to sample could
reflect variable tumor cell content in the primary specimens. All
specimens showed either an EWS/FLI1 or an EWS/ERG
transcript by RT-PCR, indicating at least some ESFT tumor cell
content. However the percentage of the specimen which was
tumor cells could not be assessed. Another source of variability
could relate to some of the other signaling pathways such as PI3-
AKT, RAS-MEK1, and PKC-delta which have been shown to
affect signaling in the HH-GLI1 pathway[14]. Nevertheless,
overall these findings indicate that primary ESFT demonstrate
significant expression of HH-GLI1 mediators and appear to
demonstrate little expression of Hedgehog species.
Multiple means of inhibition demonstrate GLI1 to be
EWS/FLI1 dependent in ESFT
Our earlier findings demonstrated that GLI1 expression is
dependent on EWS/FLI1 expression in one set of experimental
conditions using in vivo EWS/FLI1 siRNA. If GLI1 upregulation
by EWS/FLI1 is of biologic importance to ESFT, we would expect
to find such a relationship applies to multiple means of targeting
EWS/FLI1 and in multiple ESFT cell lines. Since off target effects
can produce spurious results in RNAi experiments, we assessed the
relationship between EWS/FLI1 and GLI1 activity in ESFT cell
lines using several shRNA targeting sequences. In all cases,
polyclonal cell lines were derived using lentivirally delivered shRNA
followed by rapid selection in puromycin. As is seen in Figure 2A,
the degree of EWS/FLI1 knockdown of expression mirrors the
reduction in GLI1 and of Patched1 transcript. This close
relationship is highly unlikely to have been produced by an off
target effect. It also establishes Patched1 as a target of transcrip-
tional modulation by EWS/FLI1 in ESFT cell lines.
Furthermore, similar polyclonal shRNA experiments have been
shown to yield reductions of GLI1 and of Patched1 in both A673
Figure 1. Expression of HH-GLI pathway species in primary ESFT specimens. Twelve CHTN banked tumor specimens are assessed for HH-
GLI1 related gene expression by real time quantitative PCR. Also included is TTC475 in both primary tumor specimen and cell line form. For
comparison, two Rhabdomyosarcoma (RMS-R and -T) and an Osteosarcoma (Saos) cell line are included. SaOS2 is in the upper quartile for GLI1
expression in NCI60 microarray data. For reference, TC71 cells transduced with SHH or empty retroviral vector are included in the SHH panel.
doi:10.1371/journal.pone.0007608.g001
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dependence of GLI1 expression and signaling is shared among
several well studied ESFT cell lines.
Finally, to further evaluate the soundness of this relationship, we
employed an antisense form of EWS/FLI1 and selected stable
knockdown clones from TC71 and TC32[15]. Figure 2C
demonstrates once again that an experimentally induced reduction
in EWS/FLI1 expression results in a reduction of GLI1 and
Patched1 expression.
Multiple means of GLI1 inhibition establish the
importance of GLI1 expression to ESFT phenotype
We have also demonstrated that GLI1 hairpin is capable of
diminishing anchorage independent growth in ESFT cell lines. To
r u l eo u tap o s s i b l eo f f - t a r g e te f f ect, we evaluated a panel of GLI1
shRNA targeting sequences in the ESFT cell line TC71. Figure 3A
illustrates the targeting sequences used and depicts the degree of GLI1
expression decrease and the degree of decrease in anchorage
independent growth. The consistent observation is that the degree
of GLI1 knockdown is associated with a reduction in anchorage
independent growth. Figure 3B demonstrates the efficacy of these
constructs at reducing GLI1 protein levels. These findings suggest that
GLI1 is clearly important to this aspect of tumor cell line phenotype
and that this observation is unlikely to be due to an off target effect.
To further confirm the effect of HH-GLI inhibition in ESFT,
we employed alternate means of inhibition. Suppressor of Fused
(SUFU) is an endogenous inhibitor of the HH-GLI1 pathway
acting by either cytoplasmic sequestration of GLI1 or by inhibition
of GLI1 transcription at select loci[16,17]. We drew upon our
prior observation that overexpression of Suppressor of Fused
(SUFU) is capable of diminishing anchorage independent growth
of EWS/FLI1 transformed NIH3T3 cells[4]. To see if ESFT lines
behave in a similar fashion, we transduced a total of three ESFT
lines with SUFU under the control of a high activity retroviral
promoter. High levels of SUFU transcript were exhibited by these
polyclonal lines (data not shown). Figure 3C shows that all three
lines exhibited diminished anchorage independent growth. These
experiments were verified in 2–4 independent assays per line.
They further strengthen the case that GLI1 dependence of ESFT
lines is a widespread phenomenon.
GLI1 signaling in ESFT is Hedgehog independent
The most common mechanism for activation of the HH-GLI
pathway involves activation of Smoothened, either by overexpression
Figure 2. RNAi mediated reduction in EWS/FLI1 expression results in a consistent reduction of GLI1 signaling. Panel A: Four different
shRNA sequences targeting EWS/FLI1 were introduced into the Ewing cell line TC71. The sequences are EF-2[26], EF-bp (from the Type 1 EWS/FLI1
breakpoint)[34], EF-4 [26] and EF-818 [33]. These are compared to a non-targeting control shRNA directed to a sequence in the luciferase gene by
qPCR. Reduced expression of EWS/FLI1 is always accompanied by a reduction of GLI1 and its direct target Patched1. Panel B: Similar qPCR results are
obtained from other ESFT cell lines, A673 and CHLA9. Panel C: An unrelated antisense construct inhibits EWS/FLI1 expression by Western blot (left of
panel). This reduction in EWS/FLI results similar alterations in the expression of GLI1 and Patched1 by real time qPCR (right of Panel C).
doi:10.1371/journal.pone.0007608.g002
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tumor suppressor. In EWS/FLI1 transformed NIH3T3, there is
evidence for only minimal HH activation[4]. Furthermore, expres-
sion data from primary Ewing tumor specimens does not
demonstrate significant levels of HH ligand (Figure 1). To obtain
further proof of the HH independence of GLI1 activation in ESFT,
we assessed HH activation by the application of an active form of
exogenous human SHH ligand to cells in culture. As shown on the
left in Figure 4A, application of this ligand on the HH sensitive cell
line NIH3T3 results in marked upregulation of GLI1 and of
Patched1, demonstrating an intact HH-GLI transduction pathway
with appropriate downstream signaling. The compound Cyclopa-
mine, which blocks pathway activation at the level of Smoothened,
effectively eliminates this activation as expected. In ESFT cell lines
Figure 3. Multiple means of GLI inhibition, diminish ESFT cell line phenotype. Multiple GLI1 shRNA constructs (A, bottom) produce
diminished GLI1 expression to varying degrees (Panel A, top) and diminished anchorage independent growth (Panel A, middle) in TC71. Panel B: GLI1
shRNA constructs produce the expected reduction in GLI1 protein by western blot in TC71. Panel C: Overexpression of the endogenous HH-GLI
inhibitor Suppressor of Fused (SUFU) reduces anchorage independent growth of ESFT lines.
doi:10.1371/journal.pone.0007608.g003
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upregulated by SHH to generally lesser degree, with 2/4 lines
showing no response. While this increase in GLI1 transcript can be
blocked by Cyclopamine, none of the cell lines demonstrate even a
50% enhancement of Patched1 with exogenous human SHH. So this
lesserdegreeofGLI1activationinESFTcelllinesisnotaccompanied
by any major enhanced signaling downstream of GLI1. We conclude
that, in addition to having little HH expression, ESFT cell lines are
relatively HH insensitive. The consequence of this insensitivity is
shown in Figure 4B as incubation of these lines with Cyclopamine
produces little measurable effect on anchorage independent growth.
These results contrast with the results presented above for GLI1
hairpin or overexpression of SUFU.
Cyclopamine acts on the HH-GLI pathway at the cell surface
by inhibiting the activation of Smoothened[18]. The failure of
Cyclopamine to recapitulate our shRNA and SUFU inhibitory
studies suggest that GLI1 activation is a more central phenomenon
is ESFT. To further confirm this impression we used another
means of blockade. Forskolin (FSK) is a compound which effects
cytoplasmic PKA stimulation and is known to inhibit the HH-GLI
pathway at the level of GLI1[19,20,21]. While it is not a pure
GLI1 inhibitor, it has been extensively used experimentally to
Figure 4. GLI1 upregulation is Hedgehog independent. Panel A: Exogenous SHH in culture media effectively upregulates GLI1 and Patched in
NIH3T3, an SHH responsive cell line. Cyclopamine (5 mcM) effectively blocks this stimulation. However, the same human SHH protein is relatively
ineffective in altering GLI1 expression in ESFT cell lines, with 2/4 lines showing no response. Patched1 expression is mildly altered (,50% change) in
TC32, with 3/4 lines showing no change. Statistical comparisons are made with diluent. NS means ‘‘not significant.’’ Panel B: Consistent with the
minimal expression changes produced by Cyclopamine, 10 mcM Cyclopamine is ineffective at altering anchorage independent growth in ESFT cell
lines as was observed with GLI1 shRNA. Panel C: Forskolin, which blocks the pathway at the level of GLI1 at 100 mcM concentration, has similar
inhibitory effects to those observed with shRNA and endogenous inhibitors. Panel D: Unlike Cyclopamine increasing concentrations of the specific
GLI transcriptional inhibitor GANT58 results in abrogation of anchorage independent growth in the Ewing cell line A673.
doi:10.1371/journal.pone.0007608.g004
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Figure 4C, treatment of ESFT cells with FSK results in diminished
expression of GLI1 transcript. As a consequence, anchorage
independent growth is inhibited. This further suggests that GLI1 is
important to ESFT biology and that it is activated downstream of
Smoothened.
Finally, GANT58 (NSC75503) has been shown to inhibit
transcriptional activation by GLI1 (as well as by the other GLI
species) [9]. We exposed A673 cells to increasing concentrations of
GANT58 and found a dramatic reduction in anchorage
independent growth with concentrations as low as 5 mcM. This
further supports a mechanism of activation which is downstream
of Smoothened and is consistent with the recent observation of
direct transcriptional activation of GLI1 by EWS/FLI1[5].
Some GLI1 and EWS/FLI1 transcriptional targets overlap
GLI1 is an oncogenic transcription factor. If GLI1 is more than
a peripheral event in ESFT biology, one might expect it to play a
significant role in the transcriptional profile of EWS/FLI1 in
ESFT. To evaluate this possibility, we assessed a published set of
EWS/FLI1 targets[26]. Generated in A673 cells, this data set
identified 31 genes upregulated by EWS/FLI1 as assessed by two
separate shRNA hairpin sequences combined with data on
restored expression of EWS/FLI1. In this target list, one finds
GLI1. Also on this list are NKX2.2 and GAS1, two loci known to
be affected by HH-GLI signaling. NKX2.2 is a Class II HH target
in the developing neural tube[27]. Its expression is induced in
neural ectoderm subsequent to SHH release by the notochord.
More recently, it has been shown to be directly targeted by
GLI1[28], much like Patched1. GAS1 is more indirectly involved
as part of a feedback network of SHH binding factors. An
enhancer of HH-GLI signaling, its expression is modulated based
on the signaling conditions of the target tissue. Under conditions of
low HH stimulation, GAS1 expression is enhanced; while in
conditions of strong SHH signaling, its expression is downregu-
lated[29]. Our own data indicate that the GLI1 target Patched1 is
also transcriptionally upregulated by EWS/FLI1 in multiple ESFT
lines (see Figure 2). The finding that several HH-GLI1 targets have
also been identified EWS/FLI1 targets suggests a model in which
EWS/FLI1 reaches these targets through GLI1.
To test this hypothesis, we first sought to demonstrate that
NKX2.2 and GAS1 were also EWS/FLI1 modulated targets in
TC32 and TC71, as has been shown in A673[26]. Figure 5A
demonstrates that both are indeed transcriptionally upregulated by
EWS/FLI1, based on data from cells transduced with EWS/FLI1
antisense. Next, we tested whether these EWS/FLI1-modulated
targets are also GLI1 responsive in an ESFT background. Since
TC32 cells have the lowest level of GLI1 expression of common
ESFT cell lines[4], we overexpressed GLI1 in TC32 (Figure 5B).
As direct GLI1 targets, Patched1 and NKX2.2 are upregulated by
GLI1. This supraphysiologic GLI1 expression results in downreg-
ulation of GAS1, as has been observed with prolonged SHH
stimulation in developmental models[29]. Nevertheless, the
transcript levels of all three loci are clearly GLI1 modulated in a
Ewing cell background.
As a further test that EWS/FLI1 targets these three loci through
GLI1, we measured the effect of GLI1 inhibition via GLI1
shRNA. Figure 5C demonstrates that all three loci are
transcriptionally downregulated by GLI1 hairpin, just as they
diminish with EWS/FLI1 hairpin. The fact that GAS1 is
downregulated by both GLI1 expression and by GLI1 knockdown
reflects the different states of pathway activation between the more
physiologic levels of GLI1 expression in the shRNA experiment
and the dramatic overstimulation of the pathway with GLI1
overexpression.
As an additional proof of this model, we employed a different
method of GLI1 transcriptional inhibition. The compound
GANT58 has been shown to inhibit GLI transactivation [5,9].
We have already shown that it has effects similar to GLI1 shRNA
on anchorage independent growth in an ESFT line (see Figure 4D).
If our model is correct, GANT58 should produce effects on
downstream transcriptional targets similar to those seen with GLI1
shRNA. To test this, we exposed the ESFT cell line A673 to
GANT58 at doses shown to inhibit GLI1 transactivation.
Figure 5D demonstrates the anticipated transcriptional downreg-
ulation of Patched, NKX2.2 and GAS1 by treatment with
GANT58.
Discussion
Our findings demonstrate the widespread nature of EWS/FLI1
dependent GLI1 deregulation in ESFT cell lines. Deregulated
expression of GLI1 is a characteristic of primary ESFT and many
ESFT cell lines. GLI1 expression is important to support the
malignant phenotype of ESFT cell lines whether inhibited by
shRNA, endogenous regulators, or by pharmacologic agents. This
deregulation appears to be Hedgehog independent. Finally, we
have identified the first members of a subset of EWS/FLI1 targets
which require GLI1 for their deregulation. The significant biologic
effects of GLI1 inhibition in ESFT cell lines is not surprising, since
inhibition of NKX2.2 alone is sufficient to produce similar
significant effects[26]. The biologic effects of altered expression of
our other two overlapping targets, Patched1 and GAS1 remain to
be elucidated in ESFT.
As we have observed in a model systems [4] and has been seen
in other ESFT cell lines [5], EWS/FLI1 deregulation of GLI1
appears to the a Hedgehog independent phenomenon. The
mechanism by which GLI1 is upregulated has been recently
described as being direct transcriptional upregulation by EWS/
FLI1[5]. It is gratifying that data from this publication agrees with
our hypothesis of activation of GLI1 by a Hedgehog independent
mechanism downstream of Smoothened. These observations will
enable a broader understanding of the range of activity of EWS/
FLI1 and will add to the growing literature on non-canonical
mechanisms of activating HH-GLI signaling[30].
With the recent opportunities afforded by microarray analysis, a
more consistent set of EWS/FLI1 targets is emerging[3]. Such
target sets are biased by the means by which they are identified. As
such, these methods are likely to favor targets whose transcript
levels are inherently high, such as those which may be strong
direct EWS/FLI1 transcriptional targets [31]. However, there is
no reason to assume that the list of biologically significant EWS/
FLI1 targets must necessarily be restricted to the ‘‘high amplitude’’
set favored by microarray analysis.
Given the literature suggesting that Patched1, NKX2.2, and
GAS1 are components of the HH-GLI signaling network, the most
likely model is for EWS/FLI1 induced elevation of GLI1
expression leading to altered expression of a number of target
loci. Further characterization of this system has the potential to
provide some order to the complex picture of transcriptional
deregulation by EWS/FLI1. While it is likely that only a subset of
EWS/FLI1 targets are deregulated through GLI1, the data
presented here and the known biology of HH-GLI signaling
suggest that many may be of biologic import. Since GLI1 acts as a
transcription factor, analysis of shRNA-manipulated ESFT cell
lines by expression microarray would allow the identification of
common targets of EWS/FLI1 and GLI1. Knowledge of such a
GLI1 in Ewing Tumors
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therapies. Certainly, targeting an EWS/FLI1 mediator which is
more upstream, such as GLI1, could be expected to have more
extensive effects than targeting a gene further downstream in the
process. Our work with the GLI1 inhibitor GANT58 suggests that
this pathway may be a valid target for translational research in
Ewing Sarcoma. A secondary benefit of employing GLI1
inhibition in Ewing tumors is that GLI1, unlike EWS/FLI1, is
Figure 5. EWS/FLI1 and Gli1 targets overlap in ESFT. Panel A. EWS/FLI1 antisense (see Figure 1C) demonstrates that NKX2.2 and GAS1 are
transcriptionally upregulated by EWS/FLI1 in TC71 and TC32. Panel B. GLI1 overexpression in TC32 shows that EWS/FLI1 targets PTCH, NKX2.2 and
GAS1 are transcriptionally modulated by GLI1 expression in a Ewing cell background. Panel C. GLI1 shRNA reduces GLI1 expression and also reduces
expression of these EWS/FLI1 targets. Panel D. GANT58 (10 mcM), an inhibitor of GLI transcriptional activation, results in transcriptional
downregulation of our three putative downstream targets of GLI1.
doi:10.1371/journal.pone.0007608.g005
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common malignancies. As market-driven forces generate means of
targeting this pathway in common adult malignancies[8], the
potential application of these means to patients with Ewing
Sarcoma Family Tumors promises to improve outcomes in this
difficult malignancy.
Materials and Methods
Retroviral Experiments
The generation of recombinant retroviral stocks has been
previously described [32] and in these experiments was modified
only by using the LINX-A packaging line (Genetica) for retroviral
constructs. These experiments employed either the vector system
in that description or pLXIN (Clontech, Mountain View, CA) or
the derivative pLXIH[4]. The retroviral construct for murine
SHH was previously described [4]. The retroviral construct for
Human Suppressor of Fused was obtained by PCR amplification
of the reading frame from the clone MGC3533158 (Invitrogen).
This insert was cloned into pLXIN (Clontech) or pLXIH [4].
Cloning strategy is available on request.
RNAi experiments
shRNA experiments were performed as previously described[4].
Target oligo sequences were obtained from the following publica-
tions: EF2 [26], EF4 [26], EF818 [33]. Other shRNA oligo sequences
can be found in Figure S1 accompanying this paper online.
The antisense EWS/FLI1 construct and its use has been
previously described [15].
Real Time Quantitative PCR (qPCR)
RNA was isolated using either Tri-Reagent (MRC) or RNeasy
Plus Kit (Qiagen, Valencia, CA) according to manufacturers
instructions. CDNA’s were prepared from 0.5 mcg total RNA
using the BioRad iScript Kit according to manufacturer’s
instructions. PCR was performed using a BioRad MyiQ Thermal
Cycler using BioRad iQ SYBR Green Supermix according to
manufacturer instructions (BioRad, Hercules, CA). Conditions
selected were 30 seconds of denaturation at 94uC and annealing/
extension for one minute at 60uC. Data was analyzed for
expression relative to GAPDH using the comparative Ct method
with data resulting from the average of three replica wells within
each experiment. Data in figures is represented either as a
percentage of GAPDH expression or the percent GAPDH values
have been normalized with the control value set at 1.0. Results
shown average the results of three independent experiments. Error
bars show the standard error of the mean. P values were calculated
using an unpaired Student’s t-Test. Primers for human GLI1,
GLI2, Patched1, and GAPDH have been previously described[4].
Other primers sequences are in Figure S1 online.
Cells, Cell Culture, and Materials
All tumor cell lines were grown in RPMI supplemented with
2 mM glutamine and 10% Fetal Bovine Serum at 37 degrees C
and in 5% CO2. TC71, TC32, TTC466, and TTC475 (plus
primary specimen) were kindly provided by Dr. Tim Triche.
CHLA9 was provided by Dr. C. Patrick Reynolds. A673 cells were
obtained directly from ATCC.
Primary tumor specimens were obtained from Cooperative
Human Tissue Network (CHTN) (http://www.chtn.nci.nih.gov).
RMS-R and RMS-T RNA specimens were kindly provided by Dr.
Michael Anderson. SaOS RNA was kindly provided by Dr. Daniel
Wai. We appreciate their help in this regard.
Drug Experiments
Cells were exposed to Sonic Hedgehog C24II amino-terminal
peptide (R&D Systems: http://www.rndsystems.com) for 16 hours
before RNA was extracted.
GANT58 and Forskolin (FSK) were obtained from EMD
Biosciences (http://www.emdbiosciences.com, Cat #344270).
Cyclopamine was obtained from Toronto Research Chemicals
(http://www.trc-canada.com). Drugs were dissolved in DMSO.
For expression experiments, cells were incubated with cells
overnight.
Antibodies and Immunoblotting
These were performed as previously described[4].
Soft Agar Transformation Assay
Polyclonal, selected populations of the cell type to be analyzed
were plated in soft agar at either 5000 or 15000 cells per well of a
6-well plate. The agar was made with Iscove’s medium containing
20% fetal calf serum for tumor cell lines as described previously
[32]. Drugs or diluent were added to the top layer of the agar in an
amount to achieve the target concentration in the whole well.
Drug was added only at the time of Agar setup. Agar plates were
imaged via a transilluminating flatbed scanner approximately 2–3
weeks after plating. Counts were performed manually on high
resolution scanned images. Results shown for these agar assays
were consistent over at least three independent experiments.
Lighter background color on some scanned agar images results
from acidification of phenol red in the media, a sign of enhanced
anchorage independent growth.
Reproducibility
Data presented has been repeated at least three times with
consistent results. Numerical data presented is the average of these
replicated experiments. Where necessary, results across experi-
ments have been normalized to a control value. Error bars
presented are the standard error of the mean.
Supporting Information
Figure S1 Oligonucleotide sequences
Found at: doi:10.1371/journal.pone.0007608.s001 (0.00 MB
RTF)
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